{
  "id": "6025fa371cb411341a0000be",
  "type": "yesno",
  "question": "Does hypofractionated radiotherapy offers any benefit for DIPG?",
  "ideal_answer": "No. Hypofractionated radiotherapy does not offers benefit when compared to conventional fractionated radiation therapy for DIPG.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31785177",
    "http://www.ncbi.nlm.nih.gov/pubmed/21327862",
    "http://www.ncbi.nlm.nih.gov/pubmed/33080729",
    "http://www.ncbi.nlm.nih.gov/pubmed/31728883",
    "http://www.ncbi.nlm.nih.gov/pubmed/24560760"
  ],
  "snippets": [
    {
      "text": "CONCLUSION: Hypofractionated RT for children with newly diagnosed DIPG is well tolerated and feasible from the viewpoint of reducing a patient's burden of treatment. Re-irradiation at first progression is suggested to be beneficial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31785177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Median OS and time to progression were similar between conventionally fractionated and hypofractionated RT groups.(9.7 [95% confidence interval(CI): 7.1-11.2] versus 11.0[95% CI: 5.2-13.6] months, P = 0.60; 4.2[95% CI: 1.8-8.3] versus 7.1 [95% CI:4.5-8.7] months, P = 0.38). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31785177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The median overall survival (OS) was 11\u00a0months (95% CI - 7.5 to 14.5\u00a0months) in the conventional arm and 12\u00a0months (95% CI - 10.5 to 13.5\u00a0months) in the experimental arm (p\u2009=\u20090.208). 28% (n\u2009=\u20095) patients in the experimental arm developed grade 3 or 4 hematological toxicity.CONCLUSION: The above study shows that hypofractionated radiotherapy with concurrent and adjuvant temozolomide does not improve OS and has higher hematological toxicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31728883",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The results of this meta-analysis suggest that CFRT and HFRT provide similar survival outcomes for patients with DIPG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33080729",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Hypofractionated radiotherapy offers lesser burden on the patients, their families and the treating departments, with nearly comparable results to conventional fractionation, though not fulfilling the non-inferiority assumption.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24560760",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "xternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed DIPG. However, this regimen does not seem to change overall survival in this setting.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21327862",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}